Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
25
06
2023
medline:
25
9
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
There is growing evidence supporting multidisciplinary molecular tumor boards (MTB) in solid tumors whereas hematologic malignancies remain underrepresented in this regard. The present study aimed to assess the clinical relevance of MTBs in primary refractory diffuse large B-cell lymphomas/high-grade B-cell lymphomas with MYC and BCL2 rearrangements (prDLBCL/HGBL-MYC/BCL2) (n = 13) and HGBL, not otherwise specified (NOS), with MYC and BCL6 rearrangements (prHGBL, NOS-MYC/BCL6) (n = 6) based on our previously published whole-exome sequencing (WES) cohort. For genomic analysis, the institutional MTB WES pipeline (University Cancer Center Schleswig-Holstein: UCCSH), certified for routine clinical diagnostics, was employed and supplemented by a comprehensive immunohistochemical work-up. Consecutive database research and annotation according to established evidence levels for molecularly stratified therapies was performed (NCT-DKTK/ESCAT). Molecularly tailored treatment options with NCT-DKTK evidence level of at least m2A were identified in each case. We classified mutations in accordance with biomarker/treatment baskets and detected a heterogeneous spectrum of targetable alterations affecting immune evasion (IE; n = 30), B-cell targets (BCT; n = 26), DNA damage repair (DDR; n = 20), tyrosine kinases (TK; n = 13), cell cycle (CC; n = 7), PI3K-MTOR-AKT pathway (PAM; n = 2), RAF-MEK-ERK cascade (RME; n = 1), and others (OTH; n = 11). Our virtual MTB approach identified potential molecularly targeted treatment options alongside targetable genomic signatures for both prDLBCL/HGBL-MYC/BCL2 and prHGBL, NOS-MYC/BCL6. These results underline the potential of MTB consultations in difficult-to-treat lymphomas early in the treatment sequence.
Sections du résumé
BACKGROUND
There is growing evidence supporting multidisciplinary molecular tumor boards (MTB) in solid tumors whereas hematologic malignancies remain underrepresented in this regard.
OBJECTIVE
The present study aimed to assess the clinical relevance of MTBs in primary refractory diffuse large B-cell lymphomas/high-grade B-cell lymphomas with MYC and BCL2 rearrangements (prDLBCL/HGBL-MYC/BCL2) (n = 13) and HGBL, not otherwise specified (NOS), with MYC and BCL6 rearrangements (prHGBL, NOS-MYC/BCL6) (n = 6) based on our previously published whole-exome sequencing (WES) cohort.
PATIENTS AND METHODS
For genomic analysis, the institutional MTB WES pipeline (University Cancer Center Schleswig-Holstein: UCCSH), certified for routine clinical diagnostics, was employed and supplemented by a comprehensive immunohistochemical work-up. Consecutive database research and annotation according to established evidence levels for molecularly stratified therapies was performed (NCT-DKTK/ESCAT).
RESULTS
Molecularly tailored treatment options with NCT-DKTK evidence level of at least m2A were identified in each case. We classified mutations in accordance with biomarker/treatment baskets and detected a heterogeneous spectrum of targetable alterations affecting immune evasion (IE; n = 30), B-cell targets (BCT; n = 26), DNA damage repair (DDR; n = 20), tyrosine kinases (TK; n = 13), cell cycle (CC; n = 7), PI3K-MTOR-AKT pathway (PAM; n = 2), RAF-MEK-ERK cascade (RME; n = 1), and others (OTH; n = 11).
CONCLUSION
Our virtual MTB approach identified potential molecularly targeted treatment options alongside targetable genomic signatures for both prDLBCL/HGBL-MYC/BCL2 and prHGBL, NOS-MYC/BCL6. These results underline the potential of MTB consultations in difficult-to-treat lymphomas early in the treatment sequence.
Identifiants
pubmed: 37488307
doi: 10.1007/s11523-023-00983-5
pii: 10.1007/s11523-023-00983-5
pmc: PMC10517902
doi:
Substances chimiques
Proto-Oncogene Proteins c-bcl-6
0
Proto-Oncogene Proteins c-bcl-2
0
Proto-Oncogene Proteins c-myc
0
BCL6 protein, human
0
BCL2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
749-765Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Cancer. 2022 Feb;22(2):114-126
pubmed: 34663944
Ann Oncol. 2018 Sep 1;29(9):1895-1902
pubmed: 30137196
Front Immunol. 2021 Aug 31;12:721030
pubmed: 34531868
J Clin Oncol. 2019 Jan 20;37(3):190-201
pubmed: 30523716
Genet Med. 2017 Jun;19(6):683-690
pubmed: 27906201
Lung Cancer. 2020 May;143:55-59
pubmed: 32208297
JCO Precis Oncol. 2020 Nov;4:757-766
pubmed: 35050752
BMC Cancer. 2022 Mar 3;22(1):231
pubmed: 35236331
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
J Hematol Oncol. 2021 Mar 2;14(1):39
pubmed: 33653367
Blood. 2023 Jul 13;142(2):141-145
pubmed: 37130017
Hum Mol Genet. 2018 Aug 1;27(R2):R99-R107
pubmed: 29796608
J Natl Compr Canc Netw. 2018 Oct;16(10):1161
pubmed: 30323084
Cancer Chemother Pharmacol. 2020 May;85(5):855-862
pubmed: 32236642
Cancer Discov. 2021 Nov;11(11):2780-2795
pubmed: 34112699
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32913998
Case Rep Oncol. 2017 Jun 22;10(2):548-552
pubmed: 28868010
Leukemia. 2011 Jul;25(7):1147-52
pubmed: 21494260
Nat Commun. 2021 Dec 3;12(1):7064
pubmed: 34862364
Lancet Oncol. 2020 Jul;21(7):923-934
pubmed: 32511981
Nat Med. 2019 May;25(5):744-750
pubmed: 31011206
J Cancer Res Clin Oncol. 2023 May;149(5):1905-1915
pubmed: 35796778
Front Oncol. 2023 Feb 27;13:1129405
pubmed: 36923431
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
NPJ Precis Oncol. 2021 Jun 23;5(1):59
pubmed: 34162980
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
Blood Adv. 2023 May 23;7(10):2008-2017
pubmed: 36696540
Cancer Cell. 2021 Dec 13;39(12):1643-1653.e3
pubmed: 34739844
Blood Adv. 2020 Oct 27;4(20):5226-5231
pubmed: 33104794
Haematologica. 2022 Aug 01;107(8):1850-1863
pubmed: 34788985
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
EMBO Rep. 2019 Mar;20(3):
pubmed: 30665945
N Engl J Med. 2022 Apr 21;386(16):1519-1531
pubmed: 35443108
Eur J Cancer. 2018 Jul;97:7-15
pubmed: 29734047
PLoS One. 2017 Sep 11;12(9):e0183969
pubmed: 28892521
Hered Cancer Clin Pract. 2021 Jan 9;19(1):7
pubmed: 33422121
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
ESMO Open. 2022 Oct;7(5):100573
pubmed: 36084396
Transl Oncol. 2021 Mar;14(3):101012
pubmed: 33516088
Lancet Oncol. 2021 Apr;22(4):512-524
pubmed: 33721562
Trends Cancer. 2020 Sep;6(9):738-744
pubmed: 32517959
Genes Chromosomes Cancer. 2021 May;60(5):314-331
pubmed: 33222322
J Clin Oncol. 2019 Feb 20;37(6):481-489
pubmed: 30620669
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
EClinicalMedicine. 2022 Dec 26;56:101779
pubmed: 36618900
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
JCO Precis Oncol. 2022 Oct;6:e2200132
pubmed: 36265115
Lancet. 2022 Jun 18;399(10343):2294-2308
pubmed: 35717989
Lancet Oncol. 2022 Nov;23(11):1430-1440
pubmed: 36244398
Leuk Lymphoma. 2023 Mar;64(3):738-741
pubmed: 36642966
Ann Oncol. 2018 Jul 1;29(7):1561-1568
pubmed: 29726923
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Cancer Discov. 2022 Feb;12(2):402-415
pubmed: 34551969
Blood. 2022 Feb 17;139(7):1026-1038
pubmed: 34496014
Ann Oncol. 2022 Jun;33(6):602-615
pubmed: 35263633
J Pathol Clin Res. 2022 Jul;8(4):395-407
pubmed: 35257510
Signal Transduct Target Ther. 2023 Apr 12;8(1):160
pubmed: 37045827
Cancer Sci. 2021 Sep;112(9):3627-3635
pubmed: 34159682
Biomark Res. 2020 Dec 9;8(1):71
pubmed: 33298164
Int J Cancer. 2019 Dec 1;145(11):2996-3010
pubmed: 31008532
Leukemia. 2020 May;34(5):1329-1341
pubmed: 31844144
ESMO Open. 2021 Jun;6(3):100164
pubmed: 34091263